Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C.

"Declarations Conflict of interestIn the past 3 years, Dr. Bonkovsky has received funding for clinical research studies, awarded to Atrium Wake Forest Baptist Health, from Alnylam Pharmaceuticals, Disc Medicine, Calliditas SA, Gilead Sciences, and Mitsubishi-Tanabe, NA. He has served as a consultant to Alnylam, Disc Medicine, Mitsubishi-Tanabe, and Recordati Rare Chemicals. Dr. Rudnick has served as a consultant to Alnylam Pharmaceuticals; Christopher D. Ma, Jessica Overbey, Kelly Wang, Denise Faust, Csilla Hallberg, and Karli Hedstrom report no potential conflicts; Dr. Naik has served as a consultant to Alnylam Pharmaceuticals, Disc Medicine, Mitsubishi Tanabe, and Recordati Rare Diseases; Dr. Moghe has served as a consultant to Alnylam Pharmaceuticals; Dr. Anderson has received funding for clinical studies, awarded to UTMB, from Mitsubishi-Tanabe, NA and Disc Medicine. He has served as a consultant to and on advisory boards for Alnylam Pharmaceuticals, Mitsubishi-Tanabe, NA, and Recordati Rare Chemicals; the fees for this work have gone to UTMB. Conflict of interest In the past 3 years, Dr. Bonkovsky has received funding for clinical research studies, awarded to Atrium Wake Forest Baptist Health, from Alnylam Pharmaceuticals, Disc Medicine, Calliditas SA, Gilead Sciences, and Mitsubishi-Tanabe, NA. He has served as a consultant to Alnylam, Disc Medicine, Mitsubishi-Tanabe, and Recordati Rare Chemicals. Dr. Rudnick has served as a consultant to Alnylam Pharmaceuticals; Christopher D. Ma, Jessica Overbey, Kelly Wang, Denise Faust, Csilla Hallberg, and Karli Hedstrom report no potential conflicts; Dr. Naik has served as a consultant to Alnylam Pharmaceuticals, Disc Medicine, Mitsubishi Tanabe, and Recordati Rare Diseases; Dr. Moghe has served as a consultant to Alnylam Pharmaceuticals; Dr. Anderson has received funding for clinical studies, awarded to UTMB, from Mitsubishi-Tanabe, NA and Disc Medicine. He has served as a consultant to and on advisory boards for Alnylam Pharmaceuticals, Mitsubishi-Tanabe, NA, and Recordati Rare Chemicals; the fees for this work have gone to UTMB."

"The work was supported chiefly by an investigator-initiated grant provided by Gilead Sciences, awarded to WFUSM [Dr. Bonkovsky, PI]. We thank the patients who enrolled for their participation. We thank Gilead Sciences for providing support and Harvoni for our patients in the study. Also supported by a cooperative agreement (Grant No. 1 U54 DK083909) between the NIH and the Porphyrias Consortium of the Rare Diseases Clinical Research Network, which includes funding and/or programmatic support from the National Institutes of Health Office of Rare Diseases Research and the National Institute of Diabetes and Digestive and Kidney Diseases; and by Clinical and Translational Sciences Awards from the NIH National Center for Advancing Translational Sciences to Wake Forest University School of Medicine (Grant No. 5UL1TR001420) and to the University of Texas Medical Branch (Grant No. UL1RR029876). The opinions expressed in this work are those of the authors; they do not necessarily reflect official opinions of the Gilead sciences or the US NIH. Declarations: Conflict of interestIn the past 3 years, Dr. Bonkovsky has received funding for clinical research studies, awarded to Atrium Wake Forest Baptist Health, from Alnylam Pharmaceuticals, Disc Medicine, Calliditas SA, Gilead Sciences, and Mitsubishi-Tanabe, NA. He has served as a consultant to Alnylam, Disc Medicine, Mitsubishi-Tanabe, and Recordati Rare Chemicals. Dr. Rudnick has served as a consultant to Alnylam Pharmaceuticals; Christopher D. Ma, Jessica Overbey, Kelly Wang, Denise Faust, Csilla Hallberg, and Karli Hedstrom report no potential conflicts; Dr. Naik has served as a consultant to Alnylam Pharmaceuticals, Disc Medicine, Mitsubishi Tanabe, and Recordati Rare Diseases; Dr. Moghe has served as a consultant to Alnylam Pharmaceuticals; Dr. Anderson has received funding for clinical studies, awarded to UTMB, from Mitsubishi-Tanabe, NA and Disc Medicine. He has served as a consultant to and on advisory boards for Alnylam Pharmaceuticals, Mitsubishi-Tanabe, NA, and Recordati Rare Chemicals; the fees for this work have gone to UTMB. Conflict of interest: In the past 3 years, Dr. Bonkovsky has received funding for clinical research studies, awarded to Atrium Wake Forest Baptist Health, from Alnylam Pharmaceuticals, Disc Medicine, Calliditas SA, Gilead Sciences, and Mitsubishi-Tanabe, NA. He has served as a consultant to Alnylam, Disc Medicine, Mitsubishi-Tanabe, and Recordati Rare Chemicals. Dr. Rudnick has served as a consultant to Alnylam Pharmaceuticals; Christopher D. Ma, Jessica Overbey, Kelly Wang, Denise Faust, Csilla Hallberg, and Karli Hedstrom report no potential conflicts; Dr. Naik has served as a consultant to Alnylam Pharmaceuticals, Disc Medicine, Mitsubishi Tanabe, and Recordati Rare Diseases; Dr. Moghe has served as a consultant to Alnylam Pharmaceuticals; Dr. Anderson has received funding for clinical studies, awarded to UTMB, from Mitsubishi-Tanabe, NA and Disc Medicine. He has served as a consultant to and on advisory boards for Alnylam Pharmaceuticals, Mitsubishi-Tanabe, NA, and Recordati Rare Chemicals; the fees for this work have gone to UTMB."

"Trial Registration ClinicalTrials.gov NCT03118674."